Publications by authors named "Brian Colgrove"
Background: Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) can be used in lieu of chemoradiotherapy is uncertain.
Methods: We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary tumor decreased in size by <20% or if FOLFOX was discontinued because of side effects) as compared with chemoradiotherapy.
Article Synopsis
- The study compares two treatment options for locally advanced rectal cancer: neoadjuvant FOLFOX (chemotherapy) and 5FUCRT (chemoradiation), focusing on patient experiences and outcomes.
- A multicenter trial enrolled 1,194 patients, with 940 providing data on symptoms and quality of life before and after treatment.
- Results showed that FOLFOX had fewer reports of diarrhea and better bowel function, while 5FUCRT resulted in lower rates of anxiety, nausea, and other symptoms; both treatments had distinct impacts on patients' health-related quality of life after surgery.